The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of improved TB vaccines that boost or replace BCG is a major global health goal. ID93 + GLA-SE is a fusion protein TB vaccine candidate combined with the Toll-like Receptor 4 agonist adjuvant, GLA-SE. We conducted a ph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Vaccines
Main Authors: Coler, Rhea N., Day, Tracey A., Ellis, Ruth, Piazza, Franco M., Beckmann, Anna Marie, Vergara, Julie, Rolf, Tom, Lu, Lenette, Alter, Galit, Hokey, David, Jayashankar, Lakshmi, Walker, Robert, Snowden, Margaret Ann, Evans, Tom, Ginsberg, Ann, Reed, Steven G.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6123489/
https://ncbi.nlm.nih.gov/pubmed/30210819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41541-018-0057-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados